Bellicum Pharmaceuticals has ended the only clinical trials evaluating its GoCAR-T cell product in combination with rimiducid following serious safety concerns.
Three years after the FDA rejected its initial biologic license application, Mesoblast announced its resubmission for Ryoncil. Now, the treatment is getting a second chance.
The COVID-19 research collaboration between Vir Biotechnology and GSK has largely come to an end, as Vir announced Monday it would be going it alone or with other partners.
